BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 94 filers reported holding BELLICUM PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $502,000 | +16.2% | 148,843 | +0.5% | 0.00% | 0.0% |
Q4 2018 | $432,000 | -73.3% | 148,115 | -43.6% | 0.00% | 0.0% |
Q3 2018 | $1,616,000 | +67.5% | 262,496 | +100.7% | 0.00% | 0.0% |
Q2 2018 | $965,000 | +74.8% | 130,786 | +55.4% | 0.00% | 0.0% |
Q1 2018 | $552,000 | -21.8% | 84,160 | +0.3% | 0.00% | 0.0% |
Q4 2017 | $706,000 | -26.2% | 83,921 | +1.3% | 0.00% | 0.0% |
Q3 2017 | $957,000 | +3.1% | 82,883 | +4.3% | 0.00% | 0.0% |
Q2 2017 | $928,000 | +110.4% | 79,471 | +122.3% | 0.00% | 0.0% |
Q1 2017 | $441,000 | -9.1% | 35,748 | +0.4% | 0.00% | 0.0% |
Q4 2016 | $485,000 | -27.8% | 35,608 | +5.5% | 0.00% | 0.0% |
Q3 2016 | $672,000 | +53.4% | 33,764 | 0.0% | 0.00% | 0.0% |
Q2 2016 | $438,000 | +284.2% | 33,764 | +177.9% | 0.00% | – |
Q1 2016 | $114,000 | -53.7% | 12,151 | 0.0% | 0.00% | – |
Q4 2015 | $246,000 | +39.0% | 12,151 | 0.0% | 0.00% | – |
Q3 2015 | $177,000 | -31.4% | 12,151 | 0.0% | 0.00% | – |
Q2 2015 | $258,000 | +35.1% | 12,151 | +47.2% | 0.00% | – |
Q1 2015 | $191,000 | – | 8,254 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 1,051,441 | $3,070,000 | 0.79% |
X-Square Capital, LLC | 109,832 | $321,000 | 0.25% |
KNOTT DAVID M | 111,427 | $325,000 | 0.15% |
ARK Investment Management | 1,033,491 | $3,018,000 | 0.12% |
Baker Brothers Advisors | 2,677,818 | $7,819,000 | 0.06% |
HARVEY CAPITAL MANAGEMENT INC | 31,200 | $91,000 | 0.05% |
DAFNA Capital Management LLC | 30,000 | $88,000 | 0.04% |
WASATCH ADVISORS LP | 953,368 | $2,784,000 | 0.04% |
FRANKLIN STREET ADVISORS INC /NC | 51,415 | $150,000 | 0.02% |
FARALLON CAPITAL MANAGEMENT LLC | 1,000,000 | $2,920,000 | 0.02% |